Q1 Earnings Estimate for ARTV Issued By Wedbush

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Free Report) - Analysts at Wedbush issued their Q1 2025 earnings per share estimates for shares of Artiva Biotherapeutics in a research note issued on Monday, March 24th. Wedbush analyst D. Nierengarten anticipates that the company will earn ($0.62) per share for the quarter. Wedbush currently has a "Outperform" rating and a $18.00 target price on the stock. The consensus estimate for Artiva Biotherapeutics' current full-year earnings is ($4.95) per share. Wedbush also issued estimates for Artiva Biotherapeutics' Q2 2025 earnings at ($0.66) EPS, Q3 2025 earnings at ($0.70) EPS, Q4 2025 earnings at ($0.57) EPS, FY2025 earnings at ($2.54) EPS, FY2026 earnings at ($2.68) EPS, FY2027 earnings at ($2.82) EPS and FY2028 earnings at ($2.95) EPS.

Several other research firms have also issued reports on ARTV. Cantor Fitzgerald lowered their target price on shares of Artiva Biotherapeutics from $23.00 to $20.00 and set an "overweight" rating for the company in a report on Tuesday, March 25th. HC Wainwright reissued a "buy" rating and issued a $20.00 target price on shares of Artiva Biotherapeutics in a report on Wednesday, March 26th. Finally, Needham & Company LLC reissued a "buy" rating and issued a $23.00 target price on shares of Artiva Biotherapeutics in a research note on Tuesday, March 25th. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus target price of $20.40.

Remove Ads

Artiva Biotherapeutics Trading Down 0.9 %

NASDAQ ARTV traded down $0.03 during trading hours on Thursday, reaching $3.13. 16,677 shares of the company's stock traded hands, compared to its average volume of 113,617. Artiva Biotherapeutics has a 52-week low of $3.02 and a 52-week high of $17.31. The firm has a 50-day simple moving average of $4.71 and a 200 day simple moving average of $9.19.

Institutional Trading of Artiva Biotherapeutics

Several institutional investors have recently added to or reduced their stakes in ARTV. RA Capital Management L.P. purchased a new position in shares of Artiva Biotherapeutics in the third quarter worth $152,234,000. Franklin Resources Inc. purchased a new position in Artiva Biotherapeutics in the 3rd quarter worth about $7,435,000. Geode Capital Management LLC bought a new position in Artiva Biotherapeutics during the 3rd quarter valued at about $4,774,000. Samsara BioCapital LLC bought a new position in Artiva Biotherapeutics during the 3rd quarter valued at about $4,506,000. Finally, Wellington Management Group LLP purchased a new stake in shares of Artiva Biotherapeutics during the 3rd quarter valued at about $2,912,000.

Artiva Biotherapeutics Company Profile

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.